Skip to main content

Table 1 Clinical and demographical characteristics of PsA patients and controls

From: MiR-146a G/C rs2910164 variation in South African Indian and Caucasian patients with psoriatic arthritis

 

PsA patients

(n = 117)

Controls

(n = 100)

p value

Age (years)

50.34 ± 1.14

46.23 ± 1.56

0.0309*

Sex

 Male, n (%)

63 (54)

35 (35)

 

 Female, n (%)

54 (46)

65 (65)

 

Race

 Indian, n (%)

84 (72)

62 (62)

 

 White, n (%)

32 (27)

38 (38)

 

 Mixed Race, n (%)b

1 (1)

0 (0)

 

BMI (kg/m2)

28.86 ± 0.50

27.85 ± 0.42

0.1307

Smoker

 Yes, n (%)

25 (21)

 

 No, n (%)

92 (79)

Disease duration (years)

6.43 ± 0.67

Radiology

 

 Yes, n (%)

84 (72)

 No, n (%)

33 (28)

HAQ score

0.62 ± 0.07

RF-IgM

 

 Positive, n (%)

5 (4)

 Negative, n (%)

112 (96)

Drugs

 MTX, n (%)

111 (95)

 

 SSZ, n (%)

33 (28)

 LFM, n (%)

21 (18)

 Biologics, n (%)a

9 (8)

CRP (mg/L)

 Inclusion

18.95 ± 2.81

 

0.0011*

 @ 6 month

9.68 ± 1.32

  

Plasma glucose (mmol/l)

6.17 ± 0.21

 

Total cholesterol (mmol/l)

5.11 ± 0.10

LDL cholesterol (mmol/l)

3.26 ± 0.12

HDL cholesterol (mmol/l)

1.14 ± 0.03

HbA1c (%)

5.85 ± 0.13

Vitamin D25 (ng/ml)

20.31 ± 1.34

  1. Laboratory parameters are represented as mean ± standard error. Comparisons for age, BMI and CRP levels were performed using the unpaired Student’s t-test
  2. PsA psoriatic arthritis, BMI body mass index, HAQ health assessment questionnaire, RF-IgM rheumatoid factor-immunoglobulin M, MTX methotrexate, SSZ sulfasalazine, LFM leflunomide, CRP C-reactive protein, LDL low density lipoprotein, HDL high density lipoprotein, HbA1c: blood glycated haemoglobin
  3. *A p < 0.05 was considered as being significant
  4. aBiologics: etanercept, adalimumab and infliximab. bMixed Race: Caucasian and Indian descent
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us